Carvedilol sensitizes paclitaxel-resistant gastric cancer AGS cells to paclitaxel: influences on apoptotic regulators, Notch, PI3K/AKT, ERK1/2 signaling pathways, and miR-34a expression.

The occurrence of drug resistance is a leading cause of successful therapy failure in gastric cancer patients. This study aimed to investigate the potential resensitizing effect of carvedilol (CVL) in paclitaxel (PTX) resistant gastric cancer (AGS-Rpac) cells. AGS-Rpac cells were co-treated with various concentrations of PTX and CVL.